具有细胞活性的甲基转移酶KMT9选择性抑制剂的结构导向设计
Sheng Wang1, Sebastian O Klein2, Sylvia Urban1
1Klinik für Urologie und Zentrale Klinische Forschung, Klinikum der Albert-Ludwigs-Universität Freiburg, Freiburg, Germany.
Nature communications
|January 3, 2024
概括
研究人员开发了一种强大的KMT9抑制剂KMI169,以向癌细胞增殖. 这种小分子药物有效抑制氨基甲基转移酶9 (KMT9),显示出治疗耐药前列腺癌的前景.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 药用化学 医学化学
背景情况:
- 表观遗传调节器是癌症治疗的有吸引力的目标.
- 氨酸甲基转移酶9 (KMT9) 在前列腺癌,肺癌和结肠癌的扩散中发挥作用.
- KMT9的酶活性对瘤细胞生长至关重要,将其确定为治疗点.
研究的目的:
- 开发一种强效和选择性的小分子抑制剂KMT9.9.
- 描述抑制剂的作用机制和细胞活动.
- 评估该抑制剂在治疗耐治疗癌症方面的潜力.
主要方法:
- 基于结构的药物设计被用来开发KMT9抑制剂.
- 抑制剂KMI169 (化合物4) 的特点是功效,选择性和细胞向参与.
- 评估了KMT9在调节参与细胞周期和瘤增殖的基因中的作用.
主要成果:
- 成功开发了一种强效和选择性的KMT9抑制剂KMI169.
- KMI169作为双基质抑制剂,针对SAM和基质结合口袋.
- 抑制KMT9可以选择性地降低细胞循环基因的调节,并影响各种癌细胞的增殖,包括抗性前列腺癌.
结论:
- KMI169是研究KMT9在细胞环境中的功能的一个有价值的工具.
- KMI169的开发为治疗恶性瘤的临床候选抑制剂铺平了道路.
- 向KMT9为治疗耐药癌症,特别是前列腺癌提供了潜在的治疗策略.
相关概念视频
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...